209 related articles for article (PubMed ID: 17689021)
1. The fibrosis and atrial fibrillation: is the transforming growth factor-beta 1 a candidate etiology of atrial fibrillation.
Li X; Ma C; Dong J; Liu X; Long D; Tian Y; Yu R
Med Hypotheses; 2008; 70(2):317-9. PubMed ID: 17689021
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and atrial fibrillation: is Chlamydia pneumoniae a candidate pathogen of atrial fibrillation?
Tang RB; Dong JZ; Liu XP; Ma CS
Med Hypotheses; 2006; 67(3):462-6. PubMed ID: 16793213
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines.
Shan H; Zhang Y; Lu Y; Zhang Y; Pan Z; Cai B; Wang N; Li X; Feng T; Hong Y; Yang B
Cardiovasc Res; 2009 Aug; 83(3):465-72. PubMed ID: 19398468
[TBL] [Abstract][Full Text] [Related]
4. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure.
On YK; Jeon ES; Lee SY; Shin DH; Choi JO; Sung J; Kim JS; Sung K; Park P
J Thorac Cardiovasc Surg; 2009 Jun; 137(6):1515-20. PubMed ID: 19464473
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta1: a possible risk stratification tool for atrial fibrillation.
Sovari AA; Kocheril AG
Med Hypotheses; 2008; 71(1):149-50. PubMed ID: 18329183
[No Abstract] [Full Text] [Related]
6. Examining potential therapies targeting myocardial fibrosis through the inhibition of transforming growth factor-beta 1.
Khan R
Cardiology; 2007; 108(4):368-80. PubMed ID: 17308385
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrosis and the mechanisms of atrial fibrillation.
Everett TH; Olgin JE
Heart Rhythm; 2007 Mar; 4(3 Suppl):S24-7. PubMed ID: 17336879
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-β and oxidative stress mediate tachycardia-induced cellular remodelling in cultured atrial-derived myocytes.
Yeh YH; Kuo CT; Chan TH; Chang GJ; Qi XY; Tsai F; Nattel S; Chen WJ
Cardiovasc Res; 2011 Jul; 91(1):62-70. PubMed ID: 21289011
[TBL] [Abstract][Full Text] [Related]
9. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure.
Burstein B; Comtois P; Michael G; Nishida K; Villeneuve L; Yeh YH; Nattel S
Circ Res; 2009 Dec; 105(12):1213-22. PubMed ID: 19875729
[TBL] [Abstract][Full Text] [Related]
10. Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation.
Knackstedt C; Gramley F; Schimpf T; Mischke K; Zarse M; Plisiene J; Schmid M; Lorenzen J; Frechen D; Neef P; Hanrath P; Kelm M; Schauerte P
Cardiovasc Pathol; 2008; 17(5):318-24. PubMed ID: 18402824
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway.
Gramley F; Lorenzen J; Koellensperger E; Kettering K; Weiss C; Munzel T
Int J Cardiol; 2010 Sep; 143(3):405-13. PubMed ID: 19394095
[TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
Shiroshita-Takeshita A; Brundel BJ; Burstein B; Leung TK; Mitamura H; Ogawa S; Nattel S
Cardiovasc Res; 2007 Apr; 74(1):75-84. PubMed ID: 17270161
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-β-mediated CD44/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation.
Chang SH; Yeh YH; Lee JL; Hsu YJ; Kuo CT; Chen WJ
Basic Res Cardiol; 2017 Sep; 112(5):58. PubMed ID: 28871329
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation and atrial fibrosis.
Tan AY; Zimetbaum P
J Cardiovasc Pharmacol; 2011 Jun; 57(6):625-9. PubMed ID: 21633248
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.
Bukowska A; Lendeckel U; Krohn A; Keilhoff G; ten Have S; Neumann KH; Goette A
Europace; 2008 Oct; 10(10):1212-7. PubMed ID: 18689805
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation.
Pan CH; Lin JL; Lai LP; Chen CL; Stephen Huang SK; Lin CS
FEBS Lett; 2007 Feb; 581(3):526-34. PubMed ID: 17254576
[TBL] [Abstract][Full Text] [Related]
17. Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling.
Nattel S
Circ Res; 2004 Jun; 94(11):1403-5. PubMed ID: 15192034
[No Abstract] [Full Text] [Related]
18. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72.
Wakisaka O; Takahashi N; Shinohara T; Ooie T; Nakagawa M; Yonemochi H; Hara M; Shimada T; Saikawa T; Yoshimatsu H
J Mol Cell Cardiol; 2007 Nov; 43(5):616-26. PubMed ID: 17884089
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of NF-AT3 and NF-AT4 in the atria correlates with procollagen I carboxyl terminal peptide and TGF-β1 levels in serum of patients with atrial fibrillation.
Zhao F; Zhang S; Chen Y; Gu W; Ni B; Shao Y; Wu Y; Qin J
BMC Cardiovasc Disord; 2014 Nov; 14():167. PubMed ID: 25422138
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure.
Bauer A; McDonald AD; Donahue JK
Cardiovasc Res; 2004 Mar; 61(4):764-70. PubMed ID: 14985073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
